Targeted therapy for melanoma

Cancer Treatment and Research

Volumn 167, Issue , 2016, Pages 251-262

  Wong, Deborah J L ^a   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF; Dabrafenib; MEK; Melanoma; Trametinib; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAF PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; BRAF GENE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; HUMAN; MELANOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MUTATION;

HUMANS; IMMUNOTHERAPY; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84948822881     PISSN: 09273042     EISSN: 25098497     Source Type: Book Series    
DOI: 10.1007/978-3-319-22539-5_10     Document Type: Chapter

References (52)

1. Comis RL (1976) DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60(2):165–176
2. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351(10):998–1012
3. Atkins MB et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol Off J Am Soc Clin Oncol 17(7):2105–2116
4. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
5. Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526
6. Robert C et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948):1109–1117
7. Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
8. Flaherty KT et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819
9. Ribas A., Kim K, Schuchter L, Gonzalez R, Pavlick AC, Weber J, McArthur G, Hutson TE, Flaherty K, Moschos S, Lawrence DP, Hersey P, Kefford R, Chmielowski B, Puzanov I, Li J, Nolop K, Lee R, Joe A, Sosman J (2011) BRIM-2: An open-label, multicenter Phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 29
10. Sosman JA et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714
11. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchokk GS (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc Am Soc Clin Oncol 28:611s
12. Larkin J et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876
13. Robert C et al (2014) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med
14. Long GV et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888
15. Padua RA, Barrass N, Currie GA (1984) A novel transforming gene in a human malignant melanoma cell line. Nature 311(5987):671–673
16. Sekulic A et al (2008) Malignant melanoma in the 21st century: the emerging molecular landscape. In: Mayo Clinic proceedings. Mayo Clinic vol 83(7), pp 825–846
17. Brose MS et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62(23):6997–7000
18. Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (20):2135–2147
19. Haluska FG et al (2006) Genetic alterations in signaling pathways in melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 12(7 Pt 2):2301s–2307s
20. Nazarian R et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973–977
21. Eisen T et al (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95(5):581–586
22. Ott PA et al (2010) A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 5(12):e15588
23. Bollag G et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596–599
24. McArthur GA et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15(3):323–332
25. Ascierto PA et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 31(26):3205–3211
26. Hauschild A et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365
27. Poulikakos PI et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287):427–430
28. Heidorn SJ et al (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2):209–221
29. Su F et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207–215
30. Wagle N et al (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol Off J Am Soc Clin Oncol 29(22):3085–3096
31. Shi H et al (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724
32. Poulikakos PI et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387–390
33. Greger JG et al (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11(4):909–920
34. Johannessen CM et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968–972
35. Villanueva J et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18 (6):683–695
36. Shi H et al (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4(1):80–93
37. Atefi M, von Euw E, Attar N, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Mischel P, Lo R, Ribas A (2011) Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PloS one 6(12):e28973
38. Shi H et al (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600 EB-RAF inhibition. Cancer Res 71(15):5067–5074
39. Infante JR et al (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13(8):773–781
40. Kim KB et al (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol Off J Am Soc Clin Oncol 31(4):482–489
41. Ribas A et al (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 15(9):954–965
42. Flaherty KT et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England journal of medicine 367(18):1694–1703
43. Infante JR et al (2011) Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29:p(suppl; abstr CRA8503)
44. von Euw E et al (2012) Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 11(1):22
45. Falchook GS et al (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782–789
46. Ascierto PA et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14 (3):249–256
47. Hatzivassiliou G et al (2012) ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther
48. Wong DJ et al (2014) Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer 13:194
49. Morris EJ et al (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 3(7):742–750
50. Lassen A et al (2014) Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer 13:83
51. Hu-Lieskovan S et al (2014) Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol Off J Am Soc Clin Oncol 32(21):2248–2254
52. Comin-Anduix B et al (2010) The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res Off J Am Assoc Cancer Res 16(24):6040–6048